Loading…
Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice
Infection with the ubiquitous parasite Toxoplasma gondii is a threat for immunocompromised patients and pregnant women and effective immune-prophylaxis is still lacking. Here we tested a mixture of recombinant T. gondii antigens expressed in different developmental stages, i.e., SAG1, MAG1 and GRA7...
Saved in:
Published in: | PloS one 2015-05, Vol.10 (5), p.e0126334-e0126334 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3 |
---|---|
cites | cdi_FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3 |
container_end_page | e0126334 |
container_issue | 5 |
container_start_page | e0126334 |
container_title | PloS one |
container_volume | 10 |
creator | Wagner, Angelika Schabussova, Irma Ruttkowski, Bärbel Peschke, Roman Kur, Józef Kundi, Michael Joachim, Anja Wiedermann, Ursula |
description | Infection with the ubiquitous parasite Toxoplasma gondii is a threat for immunocompromised patients and pregnant women and effective immune-prophylaxis is still lacking.
Here we tested a mixture of recombinant T. gondii antigens expressed in different developmental stages, i.e., SAG1, MAG1 and GRA7 (SMG), and a lysate derived from T. gondii tachyzoites (TLA) for prophylactic vaccination against cyst formation. Both vaccine formulations were applied systemically followed by an oral TLA-booster in BALB/c mice.
Systemic priming with SMG and oral TLA-booster did not show significant induction of protective immune responses. In contrast, systemic priming and oral booster with TLA induced higher levels of Toxoplasma-specific IgG, IgG1 and IgG2a in sera as well as high levels of Toxoplasma-specific IgG1 in small intestines. Furthermore, high levels of Toxoplasma-specific Th1-, Th17- and Th2-associated cytokines were only detected in restimulated splenocytes of TLA-vaccinated mice. Importantly, in mice orally infected with T. gondii oocysts, only TLA-vaccination and booster reduced brain cysts. Furthermore, sera from these mice reduced tachyzoites invasion of Vero cells in vitro, indicating that antibodies may play a critical role for protection against Toxoplasma infection. Additionally, supernatants from splenocyte cultures of TLA-vaccinated mice containing high levels of IFN-γ lead to substantial production of nitric oxide (NO) after incubation with macrophages in vitro. Since NO is involved in the control of parasite growth, the high levels of IFN-γ induced by vaccination with TLA may contribute to the protection against T. gondii.
In conclusion, our data indicate that prime-boost approach with TLA, but not with the mixture of recombinant antigens SMG, induces effective humoral and cellular Toxoplasma-specific responses and leads to significant reduction of cerebral cysts, thereby presenting a viable strategy for further vaccine development against T. gondii infection. |
doi_str_mv | 10.1371/journal.pone.0126334 |
format | article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1683370745</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A432516581</galeid><doaj_id>oai_doaj_org_article_3212ebee15784e52946d4f9bd6b89048</doaj_id><sourcerecordid>A432516581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3</originalsourceid><addsrcrecordid>eNqNk9tq3DAURU1padK0f1BaQ6G0kJlIlixbL4Uk9BIIpPT2KiT52OPgsVxJzuWT-pc9E09CXPJQ-8HieO0taUsnSV5SsqSsoAfnbvS97paD62FJaCYY44-SXSpZthAZYY_vjXeSZyGcE5KzUoinyU4mCCUsz3eTP199u4aFcS7E9EJb2_Y6tq5PL9u4SqO7ckOnw1qn3XXQEVLdx7aBfj81Y0x7FydOp-v2Ko4eUlenHqxbG_TpYzp4F6Htb2VhP-1AVwGNEatGezMVaozXSNlrXETt_HpaAlaODk-PDiy6W3iePKl1F-DF9ruX_Pz08cfxl8Xp2eeT48PThS0YiQuelzWRhRYMiCQWSE6kJKISnJkcY6IFGCOzzErOsqrIhM4N10LW0takMprtJa8n36FzQW1TDoqKkrGCFDxH4mQiKqfP1YABan-tnG7VTcH5RmkfW9uBYhnNwADQvCg55JnkouK1NJUwpSS8RK_F5BUuYRjNzK0ZB4WlZlQBVEYlYQXyH7arG80aKgt99LqbyeZ_-nalGnehOD4Z52jwbmvg3e8RQlTrNljoOt2DG6d9FrmUpUD0zT_ow2lsqUbjhtu-djiv3ZiqQ4w4pyIvKVLLByh8K8DDxStct1ifCd7PBMhEuIqNHkNQJ9-__T979mvOvr3HrkB3cRVcN25uXJiDfAKtdyF4qO9CpkRtOvA2DbXpQLXtQJS9un9Ad6LblmN_AbdILUQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1683370745</pqid></control><display><type>article</type><title>Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Wagner, Angelika ; Schabussova, Irma ; Ruttkowski, Bärbel ; Peschke, Roman ; Kur, Józef ; Kundi, Michael ; Joachim, Anja ; Wiedermann, Ursula</creator><contributor>Heimesaat, Markus M.</contributor><creatorcontrib>Wagner, Angelika ; Schabussova, Irma ; Ruttkowski, Bärbel ; Peschke, Roman ; Kur, Józef ; Kundi, Michael ; Joachim, Anja ; Wiedermann, Ursula ; Heimesaat, Markus M.</creatorcontrib><description>Infection with the ubiquitous parasite Toxoplasma gondii is a threat for immunocompromised patients and pregnant women and effective immune-prophylaxis is still lacking.
Here we tested a mixture of recombinant T. gondii antigens expressed in different developmental stages, i.e., SAG1, MAG1 and GRA7 (SMG), and a lysate derived from T. gondii tachyzoites (TLA) for prophylactic vaccination against cyst formation. Both vaccine formulations were applied systemically followed by an oral TLA-booster in BALB/c mice.
Systemic priming with SMG and oral TLA-booster did not show significant induction of protective immune responses. In contrast, systemic priming and oral booster with TLA induced higher levels of Toxoplasma-specific IgG, IgG1 and IgG2a in sera as well as high levels of Toxoplasma-specific IgG1 in small intestines. Furthermore, high levels of Toxoplasma-specific Th1-, Th17- and Th2-associated cytokines were only detected in restimulated splenocytes of TLA-vaccinated mice. Importantly, in mice orally infected with T. gondii oocysts, only TLA-vaccination and booster reduced brain cysts. Furthermore, sera from these mice reduced tachyzoites invasion of Vero cells in vitro, indicating that antibodies may play a critical role for protection against Toxoplasma infection. Additionally, supernatants from splenocyte cultures of TLA-vaccinated mice containing high levels of IFN-γ lead to substantial production of nitric oxide (NO) after incubation with macrophages in vitro. Since NO is involved in the control of parasite growth, the high levels of IFN-γ induced by vaccination with TLA may contribute to the protection against T. gondii.
In conclusion, our data indicate that prime-boost approach with TLA, but not with the mixture of recombinant antigens SMG, induces effective humoral and cellular Toxoplasma-specific responses and leads to significant reduction of cerebral cysts, thereby presenting a viable strategy for further vaccine development against T. gondii infection.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0126334</identifier><identifier>PMID: 26010355</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>ALLERGIC IMMUNE-RESPONSES ; Animals ; Antibodies ; Antibodies, Protozoan - blood ; Antibody Specificity - immunology ; Antigens ; Antigens, Protozoan - immunology ; Brain ; Brain - parasitology ; Brain - pathology ; Brain research ; Brain tumors ; Cells, Cultured ; Composition ; Cysts ; Cytokines ; Cytokines - biosynthesis ; Developmental stages ; DNA - metabolism ; Female ; Formulations ; Gastrointestinal Tract - parasitology ; GONDII INFECTION ; Helper cells ; HOST-CELLS ; HUMANS ; Immune response ; IMMUNIZATION ; Immunization, Secondary ; Immunocompromised hosts ; Immunoglobulin G ; Immunology ; Incubation ; Infections ; Interferon ; Intestine ; Laboratory animals ; Lymphocytes T ; Macrophages ; MAJOR SURFACE PROTEIN ; Medical Biotechnology ; Medicinsk bioteknologi ; Mice ; Mice, Inbred BALB C ; Nitric oxide ; Nitric Oxide - metabolism ; Oocysts ; PARASITE ; Parasite control ; Parasites ; Parasitology ; Patient outcomes ; PERORAL INFECTION ; Pregnancy ; PREVENTION ; Priming ; Prophylaxis ; Proteins ; Protozoa ; Protozoan Proteins - immunology ; Protozoan vaccines ; PUBLIC-HEALTH ; Recombinant Proteins - immunology ; Reduction ; Risk factors ; Rodents ; Spleen - pathology ; Splenocytes ; Tachyzoites ; Toxoplasma - immunology ; Toxoplasma gondii ; Toxoplasmosis ; Trends ; Vaccination ; Vaccine development ; Vaccines ; Vero cells ; Veterinary medicine ; Whooping cough ; γ-Interferon</subject><ispartof>PloS one, 2015-05, Vol.10 (5), p.e0126334-e0126334</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Wagner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Wagner et al 2015 Wagner et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3</citedby><cites>FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1683370745/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1683370745?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26010355$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/219037$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>Heimesaat, Markus M.</contributor><creatorcontrib>Wagner, Angelika</creatorcontrib><creatorcontrib>Schabussova, Irma</creatorcontrib><creatorcontrib>Ruttkowski, Bärbel</creatorcontrib><creatorcontrib>Peschke, Roman</creatorcontrib><creatorcontrib>Kur, Józef</creatorcontrib><creatorcontrib>Kundi, Michael</creatorcontrib><creatorcontrib>Joachim, Anja</creatorcontrib><creatorcontrib>Wiedermann, Ursula</creatorcontrib><title>Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Infection with the ubiquitous parasite Toxoplasma gondii is a threat for immunocompromised patients and pregnant women and effective immune-prophylaxis is still lacking.
Here we tested a mixture of recombinant T. gondii antigens expressed in different developmental stages, i.e., SAG1, MAG1 and GRA7 (SMG), and a lysate derived from T. gondii tachyzoites (TLA) for prophylactic vaccination against cyst formation. Both vaccine formulations were applied systemically followed by an oral TLA-booster in BALB/c mice.
Systemic priming with SMG and oral TLA-booster did not show significant induction of protective immune responses. In contrast, systemic priming and oral booster with TLA induced higher levels of Toxoplasma-specific IgG, IgG1 and IgG2a in sera as well as high levels of Toxoplasma-specific IgG1 in small intestines. Furthermore, high levels of Toxoplasma-specific Th1-, Th17- and Th2-associated cytokines were only detected in restimulated splenocytes of TLA-vaccinated mice. Importantly, in mice orally infected with T. gondii oocysts, only TLA-vaccination and booster reduced brain cysts. Furthermore, sera from these mice reduced tachyzoites invasion of Vero cells in vitro, indicating that antibodies may play a critical role for protection against Toxoplasma infection. Additionally, supernatants from splenocyte cultures of TLA-vaccinated mice containing high levels of IFN-γ lead to substantial production of nitric oxide (NO) after incubation with macrophages in vitro. Since NO is involved in the control of parasite growth, the high levels of IFN-γ induced by vaccination with TLA may contribute to the protection against T. gondii.
In conclusion, our data indicate that prime-boost approach with TLA, but not with the mixture of recombinant antigens SMG, induces effective humoral and cellular Toxoplasma-specific responses and leads to significant reduction of cerebral cysts, thereby presenting a viable strategy for further vaccine development against T. gondii infection.</description><subject>ALLERGIC IMMUNE-RESPONSES</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antibody Specificity - immunology</subject><subject>Antigens</subject><subject>Antigens, Protozoan - immunology</subject><subject>Brain</subject><subject>Brain - parasitology</subject><subject>Brain - pathology</subject><subject>Brain research</subject><subject>Brain tumors</subject><subject>Cells, Cultured</subject><subject>Composition</subject><subject>Cysts</subject><subject>Cytokines</subject><subject>Cytokines - biosynthesis</subject><subject>Developmental stages</subject><subject>DNA - metabolism</subject><subject>Female</subject><subject>Formulations</subject><subject>Gastrointestinal Tract - parasitology</subject><subject>GONDII INFECTION</subject><subject>Helper cells</subject><subject>HOST-CELLS</subject><subject>HUMANS</subject><subject>Immune response</subject><subject>IMMUNIZATION</subject><subject>Immunization, Secondary</subject><subject>Immunocompromised hosts</subject><subject>Immunoglobulin G</subject><subject>Immunology</subject><subject>Incubation</subject><subject>Infections</subject><subject>Interferon</subject><subject>Intestine</subject><subject>Laboratory animals</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>MAJOR SURFACE PROTEIN</subject><subject>Medical Biotechnology</subject><subject>Medicinsk bioteknologi</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Oocysts</subject><subject>PARASITE</subject><subject>Parasite control</subject><subject>Parasites</subject><subject>Parasitology</subject><subject>Patient outcomes</subject><subject>PERORAL INFECTION</subject><subject>Pregnancy</subject><subject>PREVENTION</subject><subject>Priming</subject><subject>Prophylaxis</subject><subject>Proteins</subject><subject>Protozoa</subject><subject>Protozoan Proteins - immunology</subject><subject>Protozoan vaccines</subject><subject>PUBLIC-HEALTH</subject><subject>Recombinant Proteins - immunology</subject><subject>Reduction</subject><subject>Risk factors</subject><subject>Rodents</subject><subject>Spleen - pathology</subject><subject>Splenocytes</subject><subject>Tachyzoites</subject><subject>Toxoplasma - immunology</subject><subject>Toxoplasma gondii</subject><subject>Toxoplasmosis</subject><subject>Trends</subject><subject>Vaccination</subject><subject>Vaccine development</subject><subject>Vaccines</subject><subject>Vero cells</subject><subject>Veterinary medicine</subject><subject>Whooping cough</subject><subject>γ-Interferon</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tq3DAURU1padK0f1BaQ6G0kJlIlixbL4Uk9BIIpPT2KiT52OPgsVxJzuWT-pc9E09CXPJQ-8HieO0taUsnSV5SsqSsoAfnbvS97paD62FJaCYY44-SXSpZthAZYY_vjXeSZyGcE5KzUoinyU4mCCUsz3eTP199u4aFcS7E9EJb2_Y6tq5PL9u4SqO7ckOnw1qn3XXQEVLdx7aBfj81Y0x7FydOp-v2Ko4eUlenHqxbG_TpYzp4F6Htb2VhP-1AVwGNEatGezMVaozXSNlrXETt_HpaAlaODk-PDiy6W3iePKl1F-DF9ruX_Pz08cfxl8Xp2eeT48PThS0YiQuelzWRhRYMiCQWSE6kJKISnJkcY6IFGCOzzErOsqrIhM4N10LW0takMprtJa8n36FzQW1TDoqKkrGCFDxH4mQiKqfP1YABan-tnG7VTcH5RmkfW9uBYhnNwADQvCg55JnkouK1NJUwpSS8RK_F5BUuYRjNzK0ZB4WlZlQBVEYlYQXyH7arG80aKgt99LqbyeZ_-nalGnehOD4Z52jwbmvg3e8RQlTrNljoOt2DG6d9FrmUpUD0zT_ow2lsqUbjhtu-djiv3ZiqQ4w4pyIvKVLLByh8K8DDxStct1ifCd7PBMhEuIqNHkNQJ9-__T979mvOvr3HrkB3cRVcN25uXJiDfAKtdyF4qO9CpkRtOvA2DbXpQLXtQJS9un9Ad6LblmN_AbdILUQ</recordid><startdate>20150526</startdate><enddate>20150526</enddate><creator>Wagner, Angelika</creator><creator>Schabussova, Irma</creator><creator>Ruttkowski, Bärbel</creator><creator>Peschke, Roman</creator><creator>Kur, Józef</creator><creator>Kundi, Michael</creator><creator>Joachim, Anja</creator><creator>Wiedermann, Ursula</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope><scope>DOA</scope></search><sort><creationdate>20150526</creationdate><title>Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice</title><author>Wagner, Angelika ; Schabussova, Irma ; Ruttkowski, Bärbel ; Peschke, Roman ; Kur, Józef ; Kundi, Michael ; Joachim, Anja ; Wiedermann, Ursula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>ALLERGIC IMMUNE-RESPONSES</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antibody Specificity - immunology</topic><topic>Antigens</topic><topic>Antigens, Protozoan - immunology</topic><topic>Brain</topic><topic>Brain - parasitology</topic><topic>Brain - pathology</topic><topic>Brain research</topic><topic>Brain tumors</topic><topic>Cells, Cultured</topic><topic>Composition</topic><topic>Cysts</topic><topic>Cytokines</topic><topic>Cytokines - biosynthesis</topic><topic>Developmental stages</topic><topic>DNA - metabolism</topic><topic>Female</topic><topic>Formulations</topic><topic>Gastrointestinal Tract - parasitology</topic><topic>GONDII INFECTION</topic><topic>Helper cells</topic><topic>HOST-CELLS</topic><topic>HUMANS</topic><topic>Immune response</topic><topic>IMMUNIZATION</topic><topic>Immunization, Secondary</topic><topic>Immunocompromised hosts</topic><topic>Immunoglobulin G</topic><topic>Immunology</topic><topic>Incubation</topic><topic>Infections</topic><topic>Interferon</topic><topic>Intestine</topic><topic>Laboratory animals</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>MAJOR SURFACE PROTEIN</topic><topic>Medical Biotechnology</topic><topic>Medicinsk bioteknologi</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Oocysts</topic><topic>PARASITE</topic><topic>Parasite control</topic><topic>Parasites</topic><topic>Parasitology</topic><topic>Patient outcomes</topic><topic>PERORAL INFECTION</topic><topic>Pregnancy</topic><topic>PREVENTION</topic><topic>Priming</topic><topic>Prophylaxis</topic><topic>Proteins</topic><topic>Protozoa</topic><topic>Protozoan Proteins - immunology</topic><topic>Protozoan vaccines</topic><topic>PUBLIC-HEALTH</topic><topic>Recombinant Proteins - immunology</topic><topic>Reduction</topic><topic>Risk factors</topic><topic>Rodents</topic><topic>Spleen - pathology</topic><topic>Splenocytes</topic><topic>Tachyzoites</topic><topic>Toxoplasma - immunology</topic><topic>Toxoplasma gondii</topic><topic>Toxoplasmosis</topic><topic>Trends</topic><topic>Vaccination</topic><topic>Vaccine development</topic><topic>Vaccines</topic><topic>Vero cells</topic><topic>Veterinary medicine</topic><topic>Whooping cough</topic><topic>γ-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, Angelika</creatorcontrib><creatorcontrib>Schabussova, Irma</creatorcontrib><creatorcontrib>Ruttkowski, Bärbel</creatorcontrib><creatorcontrib>Peschke, Roman</creatorcontrib><creatorcontrib>Kur, Józef</creatorcontrib><creatorcontrib>Kundi, Michael</creatorcontrib><creatorcontrib>Joachim, Anja</creatorcontrib><creatorcontrib>Wiedermann, Ursula</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest advanced technologies & aerospace journals</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, Angelika</au><au>Schabussova, Irma</au><au>Ruttkowski, Bärbel</au><au>Peschke, Roman</au><au>Kur, Józef</au><au>Kundi, Michael</au><au>Joachim, Anja</au><au>Wiedermann, Ursula</au><au>Heimesaat, Markus M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-05-26</date><risdate>2015</risdate><volume>10</volume><issue>5</issue><spage>e0126334</spage><epage>e0126334</epage><pages>e0126334-e0126334</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Infection with the ubiquitous parasite Toxoplasma gondii is a threat for immunocompromised patients and pregnant women and effective immune-prophylaxis is still lacking.
Here we tested a mixture of recombinant T. gondii antigens expressed in different developmental stages, i.e., SAG1, MAG1 and GRA7 (SMG), and a lysate derived from T. gondii tachyzoites (TLA) for prophylactic vaccination against cyst formation. Both vaccine formulations were applied systemically followed by an oral TLA-booster in BALB/c mice.
Systemic priming with SMG and oral TLA-booster did not show significant induction of protective immune responses. In contrast, systemic priming and oral booster with TLA induced higher levels of Toxoplasma-specific IgG, IgG1 and IgG2a in sera as well as high levels of Toxoplasma-specific IgG1 in small intestines. Furthermore, high levels of Toxoplasma-specific Th1-, Th17- and Th2-associated cytokines were only detected in restimulated splenocytes of TLA-vaccinated mice. Importantly, in mice orally infected with T. gondii oocysts, only TLA-vaccination and booster reduced brain cysts. Furthermore, sera from these mice reduced tachyzoites invasion of Vero cells in vitro, indicating that antibodies may play a critical role for protection against Toxoplasma infection. Additionally, supernatants from splenocyte cultures of TLA-vaccinated mice containing high levels of IFN-γ lead to substantial production of nitric oxide (NO) after incubation with macrophages in vitro. Since NO is involved in the control of parasite growth, the high levels of IFN-γ induced by vaccination with TLA may contribute to the protection against T. gondii.
In conclusion, our data indicate that prime-boost approach with TLA, but not with the mixture of recombinant antigens SMG, induces effective humoral and cellular Toxoplasma-specific responses and leads to significant reduction of cerebral cysts, thereby presenting a viable strategy for further vaccine development against T. gondii infection.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>26010355</pmid><doi>10.1371/journal.pone.0126334</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2015-05, Vol.10 (5), p.e0126334-e0126334 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_1683370745 |
source | Publicly Available Content (ProQuest); PubMed Central |
subjects | ALLERGIC IMMUNE-RESPONSES Animals Antibodies Antibodies, Protozoan - blood Antibody Specificity - immunology Antigens Antigens, Protozoan - immunology Brain Brain - parasitology Brain - pathology Brain research Brain tumors Cells, Cultured Composition Cysts Cytokines Cytokines - biosynthesis Developmental stages DNA - metabolism Female Formulations Gastrointestinal Tract - parasitology GONDII INFECTION Helper cells HOST-CELLS HUMANS Immune response IMMUNIZATION Immunization, Secondary Immunocompromised hosts Immunoglobulin G Immunology Incubation Infections Interferon Intestine Laboratory animals Lymphocytes T Macrophages MAJOR SURFACE PROTEIN Medical Biotechnology Medicinsk bioteknologi Mice Mice, Inbred BALB C Nitric oxide Nitric Oxide - metabolism Oocysts PARASITE Parasite control Parasites Parasitology Patient outcomes PERORAL INFECTION Pregnancy PREVENTION Priming Prophylaxis Proteins Protozoa Protozoan Proteins - immunology Protozoan vaccines PUBLIC-HEALTH Recombinant Proteins - immunology Reduction Risk factors Rodents Spleen - pathology Splenocytes Tachyzoites Toxoplasma - immunology Toxoplasma gondii Toxoplasmosis Trends Vaccination Vaccine development Vaccines Vero cells Veterinary medicine Whooping cough γ-Interferon |
title | Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T05%3A12%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prime-boost%20vaccination%20with%20toxoplasma%20lysate%20antigen,%20but%20not%20with%20a%20mixture%20of%20recombinant%20protein%20antigens,%20leads%20to%20reduction%20of%20brain%20cyst%20formation%20in%20BALB/c%20mice&rft.jtitle=PloS%20one&rft.au=Wagner,%20Angelika&rft.date=2015-05-26&rft.volume=10&rft.issue=5&rft.spage=e0126334&rft.epage=e0126334&rft.pages=e0126334-e0126334&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0126334&rft_dat=%3Cgale_plos_%3EA432516581%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c730t-458f097a63e090ce0509906d643b501217ebb922c9432d726a5b4a69f9cf0dba3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1683370745&rft_id=info:pmid/26010355&rft_galeid=A432516581&rfr_iscdi=true |